Multiple prospective clinical trials involving a total of over 3,000 subjects have clearly demonstrated the prediabetes and type 2 diabetes screening accuracy of SCOUT DS. To find out more, click on the links below.
SCOUT DS has received approval from Health Canada for commercial distribution and it has been granted a CE Mark in the European Union. US Caution: Federal law restricts the SCOUT DS system to investigational use only. Commercial distribution has not been granted by the US FDA. See SCOUT DS Operation Manual for descriptions of all relevant Warnings, Cautions, Contraindications, & Safety Information.